finance.yahoo.com ·
prestige pbh q4 2026 earnings 183647028
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPrestige PBH, a consumer health and personal care company, reported a revenue decline due to a difficult consumer environment and global conflict impacting shipments. The company's Eye Care segment underperformed, while other brands grew. The impact is company-specific, with no direct commodity or broad sector price signal. The commercial mechanism is weak: a single company's earnings miss with no clear pass-through to input costs or supply chain disruption.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Prestige PBH full-year revenue declined ~4% in fiscal 2026
- Adjusted EPS fell to $4.38
- Free cash flow was ~$246 million, slightly up from prior year
- Clear Eyes sales below expectations; Dramamine, Fleet, Hydralyte grew
- Company optimistic about returning to organic growth in fiscal 2027
Mid-term outlook for OTC healthcare products remains flat as brand loyalty offsets demand softness.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- CONSUMER_STAPLESmid
- HEALTHCARE_OTCmid